相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Ocular manifestations of anti-neoplastic immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis in cancer patients
Kevin Sheng-Kai Ma et al.
OCULAR SURFACE (2021)
Treat-to-target in axial spondyloarthritis - what about physical function and activity?
Juergen Braun et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Nonsteroidal anti-inflammatory drugs and cardiovascular risk - a matter of indication
Juergen Braun et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)
Nonsteroidal Antiinflammatory Drug Use and Association With Incident Hypertension in Ankylosing Spondylitis
Jean W. Liew et al.
ARTHRITIS CARE & RESEARCH (2020)
Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J)
Mitsumasa Kishimoto et al.
MODERN RHEUMATOLOGY (2020)
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
Atul Deodhar et al.
LANCET (2020)
Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
Stefano Gentileschi et al.
MEDIATORS OF INFLAMMATION (2020)
Risk of malignancies in patients with spondyloarthritis treated with biologics compared with those treated with non-biologics: a systematic review and meta-analysis
Yu Heng Kwan et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Safety of treatment options for spondyloarthritis: a narrative review
Salvatore D'Angelo et al.
EXPERT OPINION ON DRUG SAFETY (2018)
The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study
Marion Couderc et al.
JOURNAL OF RHEUMATOLOGY (2018)
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort
Monika Hebeisen et al.
JOURNAL OF RHEUMATOLOGY (2018)
Discontinuing tumour necrosis factor inhibitors in non-radiographic axial spondyloarthritis
Juergen Braun
LANCET (2018)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Dominique Baeten et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Desiree van der Heijde et al.
LANCET (2018)
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
Desiree van der Heijde et al.
LANCET (2018)
Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study
Anna Molto et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study
Alan J. Kivitz et al.
RHEUMATOLOGY AND THERAPY (2018)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
Joachim Sieper et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
Juergen Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis
Xenofon Baraliakos et al.
RHEUMATOLOGY (2017)
Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis
Gareth T. Jones et al.
ARTHRITIS CARE & RESEARCH (2017)
Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: A meta-analysis of randomized controlled trials
Zhigao Xu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
Michele Bally et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data
Michele Bally et al.
BMJ-BRITISH MEDICAL JOURNAL (2017)
Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3
Karel Pavelka et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
Raphael Micheroli et al.
ARTHRITIS RESEARCH & THERAPY (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality A Population-Based Study
Nisha Nigil Haroon et al.
ANNALS OF INTERNAL MEDICINE (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort
Dinny Wallis et al.
RHEUMATOLOGY (2015)
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
R. Landewe et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
Differences in physical activity patterns in patients with spondylarthritis
Emma Haglund et al.
ARTHRITIS CARE & RESEARCH (2012)
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome
Xenofon Baraliakos et al.
RHEUMATOLOGY (2011)
Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Robert D. Inman et al.
ARTHRITIS AND RHEUMATISM (2008)
Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis -: a population-based survey
Jane Zochling et al.
CLINICAL RHEUMATOLOGY (2006)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks
JC Davis et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT)
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2005)
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
X Baraliakos et al.
ARTHRITIS RESEARCH & THERAPY (2005)
分享论文
